Compare PRGO & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | AGIO |
|---|---|---|
| Founded | 1887 | 2007 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1991 | 2013 |
| Metric | PRGO | AGIO |
|---|---|---|
| Price | $12.86 | $26.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $22.50 | ★ $32.13 |
| AVG Volume (30 Days) | ★ 3.8M | 2.7M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,281,800,000.00 | $44,791,000.00 |
| Revenue This Year | N/A | $28.75 |
| Revenue Next Year | N/A | $139.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.26 |
| 52 Week Low | $12.17 | $22.24 |
| 52 Week High | $30.93 | $46.00 |
| Indicator | PRGO | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 31.06 | 35.67 |
| Support Level | $12.93 | $26.80 |
| Resistance Level | $13.63 | $28.61 |
| Average True Range (ATR) | 0.45 | 1.15 |
| MACD | 0.25 | 0.28 |
| Stochastic Oscillator | 4.17 | 16.77 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.